LONDON (Reuters) - Shire's hyperactivity drug Vyvanse will get a priority review in the United States as a potential treatment for binge eating disorder, showing a willingness by U.S. regulators to consider novel ways to fight eating problems. The U.S. Food and Drug Administration last week approved Orexigen Therapeutics's long-awaited obesity pill Contrave and an advisory panel also backed Novo Nordisk's injectable drug liraglutide for weight loss. Dublin-based Shire, which is being acquired by U.S. ...
via Health News Headlines - Yahoo News http://ift.tt/1q7lLqT
No comments:
Post a Comment